首版商保创新药目录公布 相关产品可及性有望提升

Group 1 - The "Commercial Health Insurance Innovative Drug Directory (2025)" is the first of its kind in China, focusing on high-innovation drugs with significant clinical value that exceed the basic medical insurance's "basic protection" scope [1] - A total of 121 drug generic names were reviewed for inclusion in the commercial health insurance innovative drug directory, with 19 drugs from 18 innovative pharmaceutical companies successfully included, resulting in an acceptance rate of approximately 15.7% [1] - The directory aims to complement the basic medical insurance directory, supporting the development of innovative drugs and enhancing the multi-tiered medical insurance system [1] Group 2 - The selected drugs reflect advancements in medical technology and address key areas such as Alzheimer's disease and rare diseases prevalent in children [2] - North Sea Kangcheng's drug "Gorain" is the first domestically developed enzyme replacement therapy for Gaucher disease, which has been approved for use in adolescents and adults [2] - Five domestic CAR-T products have been included in the directory, involving companies such as WuXi AppTec and Kintor Pharmaceutical [2] Group 3 - The inclusion of CAR-T products in the directory is expected to significantly reduce patient out-of-pocket expenses and improve accessibility and affordability [3] - The industry anticipates a positive impact from the inclusion of CAR-T products, enhancing commercial accessibility and supporting the growth of the pharmaceutical health sector [3] - Companies are considering expanding their supply chains and collaborating with domestic suppliers to support the rapid scaling of CAR-T products [3]